Chimerix, a biopharmaceutical company developing oral antiviral therapeutics for CMV, filed on Friday with the SEC to raise up to $85 million in an initial public offering. The Durham, NC-based company, which booked $34 million in revenue for the 12 months ended 12/31/2012, plans to list on the NASDAQ under the symbol CMRX. Morgan Stanley and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
